Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Aclarion (Nasdaq: ACON, ACONW) announced issuance of U.S. Patent #12,601,803 on April 16, 2026 for a machine learning–based system to analyze magnetic resonance spectroscopy (MRS) data. The patent covers AI-driven model training, automated data quality controls, and biomarker extraction within the cloud-based Nociscan platform.
The filing expands Aclarion's intellectual property to 64 issued and pending patents worldwide and is described as enabling scale, faster reports, reduced manual reviews, and more consistent outputs across imaging systems.
Aclarion (NASDAQ: ACON) received a Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026, recognizing its Nociscan MR spectroscopy–based SaaS platform for identifying biochemical markers of discogenic chronic low back pain.
The company cites a 97% surgical success rate when all Nociscan-positive discs are treated and notes global prevalence estimates of 266 million people with degenerative spine disease and low back pain.
Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.
The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.
Summary not available.
Aclarion (Nasdaq: ACON, ACONW) announced that its Board adopted a limited duration stockholder rights plan effective March 19, 2026 that expires in one year. The Rights Plan is intended to help stockholders realize long-term value and to reduce the likelihood of control changes without an appropriate premium.
The plan applies equally to all current and future stockholders, was adopted unanimously by the Board, and was not adopted in response to any specific acquisition proposal.
Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.
The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.
Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.
CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.
Aclarion (Nasdaq: ACON) announced that CEO Brent Ness will attend LSI USA 2026 in Dana Point, CA, March 16-20, 2026, to meet investors and potential partners.
Mr. Ness will discuss progress advancing NOCISCAN, Aclarion’s MR spectroscopy platform using biomarkers and AI to help identify painful vs non-painful spinal discs. Investors may request 1-on-1 meetings via the provided contact emails.
Aclarion (Nasdaq: ACON) published its 2026 shareholder letter outlining clinical, financial, and operational priorities. The company expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and plans a public disclosure of early interim results in Q4 2026.
Key facts: cash runway into 2028, ATM terminated in early 2025, ELOC expired December 31, 2025, and 2,882,371 fully diluted shares outstanding. The company emphasizes a cloud-delivered, software-native MedTech model and will pursue an investor-awareness program focused on institutional healthcare investors and physician education.